Tilray Brands, Inc. (TLRY), a prominent player in the cannabis industry, received a favorable upgrade from Roth Capital’s analyst Bill Kirk, who raised the stock rating to “Buy” on April 2, 2026. This upgrade comes at a time when investors are closely monitoring the stock’s performance, with a current price of $6.14 and a projected price target of $10. Kirk’s assessment reflects confidence in the company’s potential for recovery and growth, suggesting an upside of approximately 63% from its recent trading level.
Recent Price Action
In the wake of the analyst’s upgrade, TLRY has experienced notable price fluctuations. The stock traded at $6.14, a figure that represents a significant decline from its 52-week high of $127.83, underscoring a painful year for investors. In recent trading sessions, TLRY’s share price saw a change of 0.23, translating to a 3.66% increase, with a recent volume of around 3.2 million shares. The stock’s beta of 2.09 indicates a higher volatility than the broader market, which is likely part of the reason for the investor intrigue surrounding its recent performance. With the average volume nearing 3.6 million shares over the past three months, investor interest appears robust even amid challenging conditions.
Historical Performance
Evaluating TLRY’s performance over various timeframes reveals a challenging landscape for investors. Over the past 30 days, the stock has plummeted by 32.07%, while the quarterly performance indicates an even steeper decline of 43.91%. This stark decline comes against a backdrop of a broader market that has seen fluctuating trends and investor sentiment. Year-over-year, TLRY has dipped by 25.85%, compounding investor concerns. Volatility metrics are also telling; the stock has a weekly volatility rate of 5.43% and a monthly volatility of 8.19%, suggesting that risk remains a significant factor for those considering an investment.
Earnings Analysis
When assessing Tilray’s earnings, recent figures reveal both challenges and surprising outcomes. For the latest reported period on October 9, 2025, TLRY posted an earnings per share (EPS) of -$0.00022, significantly exceeding the estimated EPS of -$0.03, thus delivering a surprise of nearly 99.27%. This unexpected result indicates that while the company remains in the red, its performance was less dire than anticipated. In contrast, the prior quarter saw an EPS of $0.02 against an estimate of -$0.03, representing a 166.67% surprise to the upside. Such swings in earnings performance can be indicative of the company’s ongoing operational challenges but also highlight its capacity for unexpected resilience.
Consensus Ratings
The consensus rating for Tilray has recently shifted to a more optimistic stance with Roth Capital’s upgraded rating. Out of three total ratings, two analysts have assigned a “Buy” rating and one maintains a “Hold,” with no “Sell” ratings present. The average price target stands at $9, while the high estimate is aligned with the Roth target of $10. This growing support among analysts reflects a cautiously optimistic outlook for the stock’s recovery trajectory, suggesting a belief that TLRY could regain momentum.
Stock Grading or Fundamental View
Tilray’s Stocks Telegraph Grade stands at 41, indicating reasonable but cautious fundamentals. This score reflects mixed financial health and performance metrics, with areas of strength likely needing substantial improvement to support sustained recovery. Investors should consider this grade in conjunction with the volatility and performance trends—marking TLRY as a potentially speculative yet viable option for those with an appetite for risk.
Conclusion
For investors looking at Tilray Brands, Inc. (TLRY), the recent upgrade to “Buy” from Roth Capital comes with a significant caveat: volatility remains a prominent risk. This stock may appeal to investors targeting long-term growth in the cannabis sector, especially those comfortable with navigating market fluctuations. The risks associated with earnings unpredictability and historical performance declines warrant close scrutiny; nevertheless, the potential upside based on the recent analyst price targets makes TLRY a stock worth monitoring. As the cannabis market continues to evolve, Tilray’s positioning could either recover or face further challenges, making it a focal point for those seeking exposure to this burgeoning industry.